Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zenas BioPharma (ZBIO) Research & Development (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Research & Development data on record, last reported at $34.4 million in Q3 2025.

  • For Q3 2025, Research & Development rose 2.6% year-over-year to $34.4 million; the TTM value through Sep 2025 reached $161.5 million, up 46.29%, while the annual FY2024 figure was $139.1 million, 131.77% up from the prior year.
  • Research & Development reached $34.4 million in Q3 2025 per ZBIO's latest filing, down from $43.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $49.2 million in Q4 2024 and bottomed at $20.4 million in Q4 2023.
  • Average Research & Development over 3 years is $34.0 million, with a median of $34.1 million recorded in 2024.
  • Peak YoY movement for Research & Development: surged 140.75% in 2024, then rose 2.6% in 2025.
  • A 3-year view of Research & Development shows it stood at $20.4 million in 2023, then soared by 140.75% to $49.2 million in 2024, then tumbled by 30.02% to $34.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $34.4 million in Q3 2025, $43.0 million in Q2 2025, and $34.9 million in Q1 2025.